Introduction
============

Canakinumab (CAN), a selective, fully human, anti-interleukin-1β monoclonal antibody, has been shown to be efficacious in SJIA patients (pts) in 2 phase 3 trials: Trial 1 (4-wk, randomized placebo \[PBO\]-controlled) and Trial 2 (open-label CAN treatment \[Part 1\] followed by a randomized PBO-controlled withdrawal phase \[Part 2\]). In Trial 1, statistically significantly more CAN than PBO group pts achieved an adapted pediatric ACR 30 response and in Trial 2, CAN allowed successful reduction/discontinuation of steroids and significantly reduced risk of flare. Safety profile of CAN was in line with expectations for a biologic agent in active SJIA. The persistent disabling features of SJIA and chronic pain can have a negative impact on health-related quality of life (hrqol). These outcomes were evaluated in the CAN phase 3 program.

Objectives
==========

To report pt-reported functional ability and hrqol outcomes from the CAN phase 3 program.

Methods
=======

The phase 3 analysis included 84 pts (CAN, 43; PBO, 41) in Trial 1 and 177 pts in Trial 2 (71 from Trial 1 entered) in Part 1, and 100 rolled into Part 2 (CAN, 50; PBO, 50). Pt-reported assessments included functional ability (as measured by the Childhood Health Assessment Questionnaire \[CHAQ^©^\]), pain (measured on a visual analog scale \[VAS\] of 0-100 mm as part of the CHAQ^©^), and physical (phs) and psychosocial (pss) health status in 5-18 year old pts., according to the Child Health Questionnaire-Parent Form (CHQ-PF50).

Results
=======

In Trial 1, CAN treatment was associated with a significant improvement in CHAQ disability score (estimated difference \[ED\] of -0.69 over time vs PBO in the least square mean \[LSM\] change from baseline \[BL\] \[p = 0.0002\]), which was \~3.6 × the minimal clinically important difference of -0.19. The LSM in overall pain intensity were significantly lower (both p \< 0.0001) in the CAN group vs PBO both at Day 15 (ED, -46.42) and Day 29 (ED, -41.86). CHQ-PF50 phs and pss scores also showed significant improvements over time (ED CAN vs PBO in LSM change from BL, 12.07 and 7.28; p \< 0.005 for both). Improvements in CHAQ disability, CHQ-PF50 phs and pss, and VAS pain scores were also observed in Trial 2 (Table [1](#T1){ref-type="table"}).

###### 

Patient- or Parent-reported functional ability and hrqol parameters in Trial 2

  ----------------------------------------------------------------------------------------------
  Outcome measure, mean (SD)   Baseline\      End of Part 1\   End of Part 2\   End of Part 2\
                               CAN, N = 177   CAN, N = 177     CAN, N = 50      PBO, N = 50
  ---------------------------- -------------- ---------------- ---------------- ----------------
  **CHAQ disability score**    1.7 (0.8)      0.74 (0.9)       0.5 (0.9)        0.6 (0.8)

  **Pain (VAS, 0-100 mm)**     66.6 (23.3)    20.2 (25.8)      13.6 (26.9)      17.0 (24.2)

  **CHQ-PF50 phs score**       16.1 (14.3)    37.7 (17.2)      43.6 (17.4)      39.0 (18.1)

  **CHQ-PF50 pss score**       41.6 (11.1)    50.7 (11.1)      53.6 (11.3)      52.7 (9.8)
  ----------------------------------------------------------------------------------------------

Results are based on patients with both baseline and post-baseline values. N18 years old.

Conclusion
==========

Treatment with CAN demonstrated rapid, marked and continued improvement in patient-reported functional ability and hrqol of SJIA patients.
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